Rockefeller Capital Management L.P. Invests in Bruker Co. with 379 Share Purchase.
January 31, 2023
Trending News ☀️
Rockefeller Capital Management L.P. recently made an investment in Bruker Co. by purchasing 379 shares. Bruker Corporation ($NASDAQ:BRKR) is a leading global provider of scientific instruments and solutions for life sciences and materials research. The company manufactures and distributes a wide range of analytical instruments, from laboratory-scale to large stand-alone systems. Bruker’s products are used in a variety of industries including biotechnology, medical research, pharmaceuticals, food and beverage, energy and chemicals, and nanotechnology. The company’s flagship product line is the Bruker BioSpin magnetic resonance imaging (MRI) system. This system is used in medical research to detect and diagnose diseases, as well as in drug development to monitor the effectiveness of treatments.
Additionally, Bruker also manufactures high performance lasers, mass spectrometers, optical microscopes and atomic force microscopes for research and analysis. Bruker’s customers include universities, government laboratories, and commercial enterprises. The company also provides services such as installation, training, and maintenance for its products. Bruker’s stock is listed on the New York Stock Exchange under the ticker symbol BRKR. Rockefeller Capital Management’s recent purchase of 379 shares in Bruker Co. represents an investment in a company that provides customers with innovative scientific instruments and solutions. The company’s products are used in a variety of industries around the world, making it a great choice for investors seeking diversification. With its large portfolio of products and services, Bruker Co. has the potential to generate long-term returns for investors.
Market Price
The news has been met with mostly positive media coverage, with many investors taking it as a sign of renewed confidence in the company. On Monday, BRUKER CORPORATION stock opened at $71.7 and closed at $69.8, down by 2.6% from previous closing price of 71.6. This drop in the stock price may be attributed to the overall market uncertainty, as well as investors taking profits from the news of Rockefeller Capital Management’s investment. The company also provides solutions and services to customers in the materials and nanotechnology research, security and surveillance, and in-vitro diagnostics markets.
Given BRUKER CORPORATION’s expertise in these areas, the investment from Rockefeller Capital Management L.P. can be seen as a vote of confidence in the company’s ability to continue to provide innovative solutions to its customers. While the stock price may have dropped from the news, it is likely that it will recover in the near future as investors gain further confidence in the company’s future. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Bruker Corporation. More…
| Total Revenues | Net Income | Net Margin |
| 2.51k | 274.9 | 11.7% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Bruker Corporation. More…
| Operations | Investing | Financing |
| 241.5 | -150.9 | 25.1 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Bruker Corporation. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 3.34k | 2.38k | 6.54 |
Key Ratios Snapshot
Some of the financial key ratios for Bruker Corporation are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 7.3% | 16.2% | 17.4% |
| FCF Margin | ROE | ROA |
| 4.7% | 28.6% | 8.2% |
VI Analysis
The VI App simplifies the analysis of BRUKER CORPORATION‘s fundamentals, giving users the ability to quickly and easily evaluate its long-term potential. According to VI Risk Rating, BRUKER CORPORATION is a medium risk investment, indicating that its financial and business aspects may not necessarily be a safe bet. Although it is worth noting that this rating does not necessarily reflect the company’s future prospects. The VI App has detected one risk warning in the cashflow statement for BRUKER CORPORATION. This warning indicates that there may be underlying issues that could affect the company’s financial performance and should be taken into consideration when evaluating the company. Those interested in learning more about this risk warning are encouraged to register with us to find out more. Overall, the VI App provides a convenient way to assess BRUKER CORPORATION’s fundamentals and make better informed investment decisions. It is important to remember, however, that this assessment should not be taken as financial advice. It is recommended to do further research and speak to a qualified financial advisor before making any decisions. More…
VI Peers
Its products are used in a variety of applications, including drug discovery, food and environmental testing, and materials science research. The company’s main competitors are Tecan Group AG, Stevanato Group SPA, and Cerus Corporation.
– Tecan Group AG ($LTS:0QLN)
Tecan Group AG is a leading provider of laboratory instruments and solutions. The company has a market cap of 4.56B as of 2022 and a Return on Equity of 6.13%. Tecan provides a wide range of products and services for the life science research, diagnostics and pharmaceutical sectors. The company offers a broad range of solutions for drug discovery, genomics, diagnostics and forensics. Tecan also provides contract research services to the pharmaceutical industry.
– Stevanato Group SPA ($NYSE:STVN)
Stevanato Group SPA is a company that manufactures and sells pharmaceuticals and medical devices. The company has a market cap of 4.89B as of 2022 and a return on equity of 11.0%. The company’s products are sold in over 100 countries and it has a presence in Europe, North America, and Asia.
– Cerus Corp ($NASDAQ:CERS)
Cerus Corp is a medical technology company that specializes in blood safety. The company’s primary product is the Intercept Blood System, which is designed to inactivate viruses, bacteria, parasites, and other potentially harmful agents in donated blood. Cerus Corp’s market cap as of 2022 is 625.13M, and its ROE is -28.3%. The company has been facing some financial difficulties in recent years, but continues to invest in research and development in order to bring new products to market.
Summary
Bruker Corporation has attracted the attention of Rockefeller Capital Management L.P., which recently purchased 379 shares. Analysts believe the purchase is a positive sign for the company, as it reflects confidence in their potential for growth. Bruker is a leading innovator in the field of scientific instruments and materials analysis, offering a wide range of tools and technologies that enable researchers to make discoveries and measure materials with unprecedented accuracy.
The company has a strong portfolio of products and services and is well-positioned to capitalize on new opportunities. With the backing of Rockefeller Capital Management, Bruker is primed for continued success in the coming years.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
